Cixutumumab
Robatumumab
Figitumumab
Teprotumumab
Xentuzumab
Ganitumab
Dalotuzumab
Istiratumab
Lonigutamab
Veligrotug
Dusigitumab
AZ7550 hydrochloride
AZ7550
IGF-I (24-41) (TFA)
IGF-I (30-41) (TFA)
IGF-1R inhibitor-2
AZ12253801
Mecasermin
Chimaphilin
AG 538